Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S9-S10, June 2016

Chimeric Antigen Receptor Gene-Modified Virus-Specific T-Cell Expanded in Patients with Reactivated Epstein-Barr Virus Post Allogeneic Stem Cell Transplant

      We recently reported the safety of allogeneic virus-specific T cells (VSTs) expressing a chimeric antigen receptor (CAR) for CD19 (CD19.CAR-VSTs) for the treatment of patients with relapsed B-cell malignancies after HSCT (Cruz et al, Blood 2013). However, the CAR-VSTs did not expand as expected after infusion, even in the presence of viral reactivation. During manufacture, VSTs were cultured ex vivo for 19 days before transduction (late-transduced) with CAR and we hypothesized that by this time, sufficient T-cell differentiation may have occurred limiting their proliferative capacity. To test this hypothesis, we developed and optimized a good manufacturing practices (GMP) compliant method for the early transduction of tri-VSTs directed to Epstein-Barr virus, adenovirus and cytomegalovirus with CAR directed to CD19.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect